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Key Questions
 What indirect effects from pediatric PCV13 use were observed among 
adults aged ≥65 years before 2014?
 What effects from PCV13 use have we observed among adults aged ≥65 
years since 2014? 
 What additional benefits are expected from continued PCV13 use among 
adults aged ≥65 years given the remaining disease burden?
Population Covered by the Policy Question
Adults ≥65 years old without an immunocompromising condition are included in the 
current policy discussion
Not included in the current policy discussion:
 Adults ≥19 years old with an immunocompromising condition including:
– Recommended to receive PCV13 in series with PPSV23 (ACIP 2012)
• Chronic renal failure 
• Nephrotic syndrome 
• Immunodeficiency 
• Iatrogenic immunosuppression
• HIV
• Cochlear implants
• CSF leaks
• Generalized malignancy
• Hodgkin disease
• Leukemia or Lymphoma
• Multiple myeloma
• Solid organ transplants
• Congenital or acquired asplenia
• Sickle cell disease or other hemoglobinopathies
What indirect effects from pediatric 
PCV13 use were observed among adults 
aged ≥65 years?
Indirect Effects on IPD in Adults ≥65 Years Old
Key Points
 Nine-fold reduction in 
PCV13-type IPD from 2000 
through 2014 
 Three-fold reduction in 
PCV13-type IPD after 
PCV13 introduction for 
children (2010-2014)
1Active Bacterial Core Surveillance, unpublished data
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Indirect Effects on Pneumonia in Adults ≥65 Years Old
 Reductions in all-cause pneumonia in adults ≥65 years old were 
demonstrated after pediatric PCV7 introduction in 20001
 Analysis of Healthcare Cost and Utilization Project (HCUP) data 
between 2010-2014 demonstrated2
–
–
No reductions in all-cause pneumonia 
Decline in pneumococcal pneumonia
• -35% (-40% to -17%) for adults 65-74 years
• -20% (-40% to 8%) for adults ≥75 years
1Tsaban et al. 2017
2Lessa ACIP October 2018
What indirect effects from pediatric PCV13 
use were observed among adults ≥65 years by 
age, race, ethnicity, and underlying chronic 
medical conditions?
Indirect Effects by Age
Key Points
 Indirect effects 
observed for all age 
groups
 Disparities by age 
in PCV13-type 
disease reduced 
but not eliminated
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1Active Bacterial Core Surveillance, unpublished data
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Indirect Effects On PCV13-type IPD Incidence Among Older Adults 
by Race and Ethnicity
Key Points
 Indirect effects reduced PCV13-type IPD among 
adults of black race1, Navajos2, and Alaska Natives3
 Disparities in PCV13-type IPD for Alaska Natives and
Navajos vs the general population reduced but not 
eliminated
1 Active Bacterial Core Surveillance, unpublished data
2 John Hopkins Center for American Indian Health, unpublished data
3CDC, Arctic Investigations Program, unpublished data 
≥65 Years Old of Black and White Race, 2008–20141
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Indirect Effects by Underlying Medical Conditions
.
IPD Incidence per 100,000 Adults ≥65 Years Old1
Serotype group Pre-PCV13 
2007-2008 (95%CI)
Post-PCV13 
2013-2014 (95%CI)
Percent change
(95%CI)
Healthy Overall 27.0 (25,30) 15.4 (14, 17) -43 (-50,-35)
PCV13 12.8 3.7 -71 (-77,-64)
CMC* Overall 51.6 (48,55) 35.4 (33,38) -31 (-37,-25) 
PCV13 21.4 6.8 -68 (-72,-63) 
*Chronic medical conditions (CMC) include chronic heart, liver, and lung disease, diabetes, alcohol abuse, and cigarette smoking
Key Point
 Percent reduction from indirect effects are similar among older adults with and 
without CMC
1Active Bacterial Core Surveillance, unpublished data
What effects from PCV13 use have we 
observed among adults aged ≥65 years 
since 2014?
PCV13 effectiveness and safety
Summary of Evidence Supporting PCV13 Use Among 
Adults >65 Years Old in 2014
 Prevents IPD and non-bacteremic pneumonia
–
–
75% reduction in vaccine type IPD
45% reduction in vaccine type non-bacteremic pneumonia
 Safety demonstrated in clinical trials
 In 2014, GRADE evaluation demonstrated strong quality evidence 
supporting PCV13 use in series with PPSV23 for all adults ≥65 years
PCV13 Effectiveness and Safety: GRADE Summary in 2019 
Type Outcomes Individual-Level Effectiveness
Benefits
PCV13-type IPD VE: 47–75%
PCV13-type non-bacteremic
pneumococcal pneumonia (NIPP) VE: 38–71%
All-cause pneumonia VE: 6–11%
PCV13-type disease mortality Limited data, but no VE demonstrated
Harms Serious adverse events associated with PCV13
No new safety signals or unexpected 
patterns observed
Key Points
 Post licensure observational studies demonstrate that PCV13 is safe and effective 
 GRADE analysis consistent with 2014 findings
PCV13 uptake among adults ≥65 years 
What effects from PCV13 use have we 
observed among adults aged ≥65 years 
since 2014?
Population-level impact: 
combined direct and indirect effects
Population-Level Impact on IPD 
IPD Incidence Among Adults ≥65 Years Old, 2013–20171
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Key Point
 No changes in IPD 
incidence since 2014
– No direct or indirect 
effects observed at the 
population level since 
2014
 Non-PCV13 serotypes now 
make up the majority of 
the disease burden
1Active Bacterial Core Surveillance, unpublished data
PCV13 introduction for 
adults ≥65 years old
Population-Level Impact on PCV13-type IPD Associated Deaths
.
PCV13-type Mortality Among Adults ≥65 Years Old, 2013-20171
Key Points
 No population-level impact 
on mortality associated 
with PCV13-type IPD since 
2014
 No changes in case fatality 
ratio
1Active Bacterial Core Surveillance, unpublished data
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Non-invasive pneumococcal pneumonia1
PCV13 introduction 
for adults ≥65 
years old
Population-Level Impact on Non-Invasive and Invasive Pneumonia
Key Points: 
 Decline in non-invasive pneumonia observed between 2013 and 2014 (indirect effects)
 No further population-level impact on non-invasive or invasive pneumonia since 2014
Invasive pneumococcal pneumonia incidence2
PCV13 introduction for 
adults ≥65 years old
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1Gierke. ACIP October 2018. Surveillance for Non-Invasive Pneumococcal Pneumonia (SNiPP), unpublished data 
2Active Bacterial Core Surveillance (ABCs), unpublished data
Population-Level Impact on PCV13-type Pneumonia1
Jun 2014 – May 2015
Incidence per 100,000 (95%CIx)
Jun 2015 – May 2016
Incidence per 100,000 (95%CIx)
Absolute
Difference
% Relative
Reduction
≥65y All
Indirect Effects
PCV13 coverage 11%, May 2015†
Indirect and Direct Effects
PCV13 coverage 36%, May 2016†
All-cause CAP 2412 (2317, 2511) 2080 (1992, 2172) 332 13.8 (8.5, 18.7)
PCV13-type CAP 112 (93, 135) 76 (61, 96) 36 31.5 (8.3, 48.9)
% of CAP Caused by 
PCV13 Serotypes  4.6% 3.7%
Key Points:
 Population-level impact on PCV13-type pneumonia and all-cause pneumonia
 PCV13-type pneumonia ~4% of all-cause pneumonia
1 Swerdlow. ACIP June 2018. Pfizer, Louisville Cohort Study, unpublished data.
x95% confidence interval is based on Poisson distribution.  
†Uptake estimates are specific to Louisville (Jefferson County) Kentucky and were based on IQVIA administrative claims (numerator) and US Census data (denominator).
CAP=community-acquired pneumonia; PCV13=13-valent pneumococcal conjugate vaccine; SSUAD=PCV13 serotype-specific urinary antigen detection assay. 
What additional benefits are expected 
from continued PCV13 use among 
adults ≥65 years given the remaining 
disease burden?
Current PCV13 Burden Among Adults ≥65 Years Old
 PCV13-type IPD incidence 5/100,000 (20% of all IPD)a
–
–
Common PCV13 serotypes (% of PCV13-types): 3 (66%), 19A (13%), 7F 
(13%), 19F (12%)a
 PCV13-type pneumonia incidence ~17b–76c/100,000 (~4% of all pneumonia)
Common PCV13 serotypes (% of PCV13-types): 3 (37%), 19A (28%), 6A 
(12%), 5 (9%), 7F (7%)c
aActive Bacterial Core Surveillance (ABCs), unpublished data
bGierke. ACIP October 2018. Surveillance for Non-Invasive Pneumococcal Pneumonia (SNiPP), unpublished data
cSwerdlow. ACIP June 2018. Pfizer, unpublished data
Estimated Public Health Impact: Cases Averted
Over the Lifetime of the Cohort (2.7 Million Adults 65 Years Old)
CDC 2018 
(PCV13 VE for ST3 IPD 
and ST3 pneumonia 0%)
CDC 2018 
(PCV13 VE for ST3 IPD 26% 
and ST3 pneumonia 45%)
Pfizer 2018 
(PCV13 VE for ST3 IPD 26% 
and ST3 pneumonia 45%)
IPD Cases -76 -84 -175
Hospitalized Pneumonia Cases -2,047 -5,262 -2,826
Non-hospitalized Pneumonia Cases -2,205 -5,611 -2,965
Deaths due to IPD -10 -11 -25
Deaths due to Pneumonia -79 -207 -199
QALYs 709 1,624 1,542
Life-years 1,101 2,611 1,865
Total Cost $398 $361 $306
Medical Costs -$25 -$63 -$51
Vaccine Costs $423 $423 $357
Cost/QALY $561,417 $222,132 $199,000
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Estimated Public Health Impact: Cases Averted and Cost
Over the Lifetime of the Cohort (2.7 Million Adults 65 Years Old)
CDC 2018 
(PCV13 VE for ST3 IPD 
and ST3 pneumonia 0%)
CDC 2018 
(PCV13 VE for ST3 IPD 26% 
and ST3 pneumonia 45%)
Pfizer 2018 
(PCV13 VE for ST3 IPD 26% 
and ST3 pneumonia 45%)
IPD Cases -76 -84 -175
Hospitalized Pneumonia Cases -2,047 -5,262 -2,826
Non-hospitalized Pneumonia Cases -2,205 -5,611 -2,965
Deaths due to IPD -10 -11 -25
Deaths due to Pneumonia -79 -207 -199
QALYs 709 1,624 1,542
Life-years 1,101 2,611 1,865
Medical Costs -$25 -$63 -$51
Vaccine Costs $423 $423 $357
Total Cost $398 $361 $306
Cost/QALY $561,417 $222,132 $199,000
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Annual Number Needed to Vaccinate (NNV) Among 
Adults ≥65 Years Old*
Outcome
PCV13-type:
Incidence per 
100,000
Vaccine 
Effectiveness (VE) (95%CI) NNV (range)
IPD 5a 76%b (48, 89) 26,300 (22,500, 41,700)
Inpatient
Pneumonia 17c–76d 43%e (12, 63) 3,000–14,000 (2,100, 50,200)
Outpatient
Pneumonia 88f 43%e (12, 63) 2,600 (1,800, 9,500)
*Calculation: NNV= 1/(incidence rate x VE)
a Active Bacterial Core Surveillance, unpublished data
b Bonten et al. CAPiTA. 2015.
c Gierke. ACIP October 2018. Surveillance for Non-Invasive Pneumococcal Pneumonia (SNiPP), unpublished data—
estimated by applying the %PCV13-type IPD to the NIPP incidence estimate
d Swerdlow. ACIP June 2018. Pfizer, unpublished data
e Webber et al. CAPiTA. 2017.
f Nelson et al. 2008, estimated as 5.1% of all-cause outpatient pneumonia is PCV13-type
Additional Considerations and 
A Summary of the Evidence to 
Recommendations Framework
Values and Preferences of Older Adults Regarding 
PCV13 Use
 Evidence: Few studies focus on older adult perceptions of PCV13 specifically
• Pneumonia perceived as severe (more so than influenza), 
sometimes fatal illness1-3
• Low perceived personal susceptibility to pneumonia1-2
 Workgroup perspective: Potential protection against pneumonia likely 
outweighs the side effects of PCV13 for older adults 
1 Doshi et al. 2016
2 Brown et al. 2017 (PPSV23 only)
3 Kaljee et al. 2017
Acceptability of Continued PCV13 Use
 Limited studies assessing acceptability among stakeholders:
–
–
–
–
Current recommendations are confusing for providers1
Providers recommended continuing with current recommendation2
Keeping the current recommendations may be best programmatically if new conjugate 
vaccines available soon3
Reimbursement for vaccine is still a programmatic issue3
 Frequent changes in recommendations may negatively impact the perceived 
importance of future adult vaccine recommendations 
 PCV13 provides individual-level protection for the remaining PCV13 disease burden
 PCV13 provides minimal public health benefit due to the low remaining disease 
burden
1 Hurley et al. 2018
2 Pfizer sponsored provider survey, unpublished, 2018
3 Association of Immunization Managers (AIM) survey, unpublished, 2018
Feasibility Considerations
 Recommendations are complex, but integrated into many health care and 
public health systems
 Frequent changes to recommendations could present implementation 
challenges
 Universal age-based recommendations are easier to effectively implement 
than risk-based ones
 Effective communication strategies will be needed if a policy change occurs
Key Issues from the EtR
Element Favoring Continued PCV13 Use Favoring No Longer using PCV13
Burden of 
Disease
•
•
•
•
•
•
PCV13-type disease reduced, but not eliminated 
through indirect effects from pediatric PCV use
• Indirect effects from pediatric PCV use have 
reduced the burden of PCV13-type disease to 
historic lows
Benefits PCV13 effective in preventing PCV13-type 
pneumococcal disease
• Impact from PCV13 use in older adults observed to 
date is minimal; no impact on IPD and inconsistent 
findings across studies for impact on pneumonia
• Benefits from continued PCV13 use are expected 
to be minimal
Acceptability Frequent changes in recommendations may 
negatively impact the perceived importance of 
future adult vaccine recommendations
• Credibility comes from evidence-based 
recommendations
Resources 
Used
A recommendation change would incur a cost to 
update electronic medical records, decision support 
tools, etc.
• Economic analyses results do not favor continued 
PCV13 use 
Feasibility Universal prevention strategies are easier to 
implement effectively than risk-based ones 
Frequent changes in recommendations present 
implementation challenges
• Simplifies the recommendations—current 
recommendations have been confusing and 
difficult to implement
Proposed Policy Options 
A. Recommend PCV13: “ACIP recommends PCV13 for all adults 65 years or older who 
have not previously received PCV13. PCV13 should be given first, followed by a dose of 
PPSV23.”
B. Shared clinical decision making: “ACIP recommends PCV13 based on shared clinical 
decision making for adults 65 years or older who do not have an immunocompromising 
condition* and who have not previously received PCV13. All adults 65 years or older 
should receive a dose of PPSV23.”
C. No longer recommend PCV13: “ACIP no longer recommends PCV13 for adults 65 years 
or older who do not have an immunocompromising condition.* All adults 65 years or 
older should receive a dose of PPSV23.”
*Immunocompromising conditions defined as chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic 
immunosuppression, generalized malignancy, HIV, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplants, 
cochlear implants, CSF leaks, congenital or acquired asplenia, sickle cell disease, or other hemoglobinopathies. 
Guidance for PCV13 and PPSV23 Use Based on the 
Proposed Policy Options
 A. Recommend PCV13
– Current guidance for PCV13 in series with PPSV23 would be unchanged
 B. PCV13 recommended based on shared clinical decision making 
– Guidance will be updated to reflect options for PCV13 and PPSV23 in 
series and PPSV23 alone
 C. No longer recommend PCV13 
– Pre-2014 policy guidance would apply, i.e. PPSV23 alone 
Discussion
Proposed Policy Options 
A. Recommend PCV13: “ACIP recommends PCV13 for all adults 65 years or older
who have not previously received PCV13. PCV13 should be given first, followed by 
a dose of PPSV23.”
B. Shared clinical decision making: “ACIP recommends PCV13 based on shared 
clinical decision making for adults 65 years or older who do not have an 
immunocompromising condition and who have not previously received PCV13. All 
adults 65 years or older should receive a dose of PPSV23.”
C. No longer recommend PCV13: “ACIP no longer recommends PCV13 for adults 
65 years or older who do not have an immunocompromising condition. All adults 
65 years or older should receive a dose of PPSV23.”
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thank you!
